News

August 14, 2019

Proof of Concept trial results for Staccato Alprazolam has neurology community cautiously optimistic

Speed of onset action is encouraging; additional research on other epilepsy patient subsets an important next step. Read more here: https://journals.lww.com/neurotodayonline/Pages/articleviewer.aspx?year=2019&issue=08080&article=00009&type=Fulltext
August 2, 2019

Engage Therapeutics CEO and Founder Greg Mayes selected to present at the 2020 Emerging MedTech Summit.

Greg Mayes, Engage Therapeutics’ CEO and Founder, will join other Life Science Intelligence leaders at the Ritz Carlton Laguna Niguel in Dana Point, CA February 18 […]
July 9, 2019

Engage Therapeutics Announces Data from Phase 2a, Proof-of-concept Study of Staccato Alprazolam to Suppress Seizures in Patients with Epilepsy Published in Epilepsia

This proof-of-concept study referenced in this peer-reviewed journal demonstrated that three doses of Staccato alprazolam (0.5 mg, 1.0 mg, and 2.0 mg) rapidly suppressed epileptic activity […]
July 1, 2019

Interview with Engage Therapeutics’ founder Greg Mayes appears in Epilepsy Foundation’s June 2019 Research Quarterly

Greg discusses his personal connection to epilepsy and the challenges his company faces in finding the perfect study participants for the clinical trial of Staccato Alprazolam, […]
July 1, 2019

Engage Therapeutics sponsors Kurt Eichenwald’s Miami appearance to discuss “A Mind Unravled,” a chronicle of his life with epilepsy.

MIAMI, July 01, 2019 (GLOBE NEWSWIRE) — New York Times bestselling author Kurt Eichenwald will be at the Mayfair Hotel and Spa in Coconut Grove on […]
May 6, 2019

Engage Therapeutics Presents Data from Part 1, Open-label Run-in of StATES Phase 2b Study of Staccato® Alprazolam at 2019 American Academy of Neurology Annual Meeting

Eight (8) patients with predictable generalized or focal epileptic seizures treated with Staccato alprazolam  62.5 percent of patients respond with cessation of seizure activity within two […]
March 13, 2019

Engage Therapeutics to Present Phase 2b Open Label Run-in Data from StATES Trial of Staccato Alprazolam at 2019 American Academy of Neurology Annual Meeting

SUMMIT, N.J., March 11, 2019 /PRNewswire/ — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people who experience […]
February 11, 2019

How Engage Therapeutics Is Improving Life With Epilepsy

International Epilepsy Day is here! With individuals and organizations sharing stories of taking action, we thought we’d take the opportunity to reflect on what the team […]
December 3, 2018

Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion

On December, 3, 2018, Engage Therapeutics announced at the American Epilepsy Society’s Annual Meeting the successful completion of the open label portion of the StATES (Staccato […]
October 22, 2018

Engage Therapeutics board member is named one of TIME’s “The Health Care 50” for epilepsy research

Engage Therapeutics board member is named one of TIME’s “The Health Care 50” for epilepsy research: Health Care 50 | Time.com